Featured Research

from universities, journals, and other organizations

Still hope for GAD diabetes vaccine, researchers believe

Date:
June 22, 2011
Source:
Lund University
Summary:
Despite the disappointing results in trying to treat children suffering from type 1 diabetes with the GAD vaccine, the treatment has not been written off entirely. DIAPREV-IT, the study in which healthy high-risk children are vaccinated, is continuing as planned, and now with more money behind it.

Despite the disappointing results in trying to treat children suffering from type 1 diabetes with the GAD vaccine, the treatment has not been written off entirely. DIAPREV-IT, the study in which healthy high-risk children are vaccinated, is continuing as planned, and now with more money behind it.

Related Articles


"I am still hopeful that the GAD vaccine will work," says Helena Elding Larsson.

Dr Elding Larsson is a paediatrician at Skεne University Hospital in Malmφ, Sweden, and a researcher at Lund University's Diabetes Centre. She is leading the DIAPREV-IT research project. The Juvenile Diabetes Research Foundation (JDRF) in the USA, the world's largest funder of research on type 1 diabetes, also believes in DIAPREV-IT. It recently awarded the project USD 495 000 (over SEK 3 million) in a three-year grant.

At the beginning of May, the company Diamyd, which manufactures the GAD vaccine, reported that the attempts to halt the destruction of the insulin-producing beta cells in children who have recently fallen ill with type 1 diabetes had not produced any positive results. The European part of the study was therefore ended. The results from a similar study in the US are not expected for another year.

Different conditions for GAD vaccine in DIAPREV-IT

DIAPREV-IT is the first and so far only study in which healthy children at high risk of developing diabetes are vaccinated. The children should have risk genes for type 1 diabetes and at least two antibodies against beta cells, which is a sign that the immune system is starting to attack the cells. "We know that the risk of these children developing diabetes is very high," says Helena Elding Larsson.

It is only once the majority of all the beta cells have been destroyed that the disease breaks out.

"Because we are vaccinating children earlier in the disease process, they have more beta cells left that can be saved. This should mean that there is a greater chance the vaccine will have an effect."

Another difference that could be significant is that some of the children are younger. The lower age limit in DIAPREV-IT is four.

"We will not know for another five years whether it has worked or not, and if it does, a larger study must be carried out to confirm the results," says Helena Elding Larsson. "Because the GAD vaccine doesn't have any side effects, I think it would be wrong not to pursue DIAPREV-IT to its completion. There is a possibility that it will succeed, and so we cannot pass up this opportunity."


Story Source:

The above story is based on materials provided by Lund University. Note: Materials may be edited for content and length.


Cite This Page:

Lund University. "Still hope for GAD diabetes vaccine, researchers believe." ScienceDaily. ScienceDaily, 22 June 2011. <www.sciencedaily.com/releases/2011/06/110622072750.htm>.
Lund University. (2011, June 22). Still hope for GAD diabetes vaccine, researchers believe. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2011/06/110622072750.htm
Lund University. "Still hope for GAD diabetes vaccine, researchers believe." ScienceDaily. www.sciencedaily.com/releases/2011/06/110622072750.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) — Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins